



PRESS RELEASE

Trillium recognized with national award

Toronto, Canada – May 26, 2005 - Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, today announced that it has been awarded BIOTECanada's "2005 Promising Early Stage Company" Award.

BIOTECanada is the national association representing the broad spectrum of biotech constituents including the health, agricultural, environment, and industrial sectors, as well as academic and research institutions and other organizations dedicated to the long term and sustainable development of biotechnology, its practices and products. Each year, BIOTECanada proudly recognizes those individuals and companies who have demonstrated significant accomplishments, exemplary leadership and commitment to the biotech industry in Canada and to the national association.

"It's always encouraging to be recognized for one's accomplishments, particularly by such an important and respected national organization as BIOTECanada", commented Dr. Niclas Stiernholm, TTI's Chief Executive Officer. "Every single individual at TTI should feel proud of this award, because it is the result of hard work by a dedicated team committed to achieving its goals."

About Trillium:

Trillium Therapeutics Inc. is a private research and development company specializing in innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses. These include autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases. The Company identifies early-stage therapeutic candidates with promising preclinical profiles and advances these towards clinical testing, with the primary objective of demonstrating safety and efficacy in humans. TTI currently has three

programs, two targeting the CD200 immunoregulatory axis and a third that focuses on pro-inflammatory cytokine receptor antagonists. The company has a broad network of external academic and industry R&D collaborations.

- 30 -

For more information, please contact:

Niclas Stiernholm, Ph.D.
Chief Executive Officer
Trillium Therapeutics Inc.
96 Skyway Avenue
Toronto, Ontario, M9W 4Y9
Canada

Tel: (416) 595-0627
Fax: (416) 595-5835
niclas@trilliumtherapeutics.com
www.trilliumtherapeutics.com